Prostate disease in older men: 2. Cancer

Hospital Practice

Volumn 32, Issue 10, 1997, Pages 159-181

  Albertsen, Peter C ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SURVIVAL; EARLY DIAGNOSIS; HUMAN; MALE; PROSTATE CANCER;

EID: 0030805326     PISSN: 87502836     EISSN: None     Source Type: Journal    
DOI: 10.1080/21548331.1997.11443584     Document Type: Article

References (23)

1. Albertsen PC: Early-stage prostate cancer: When is observation appropriate? Hematol Oncol Clin North Am 10:611, 1996
2. Albertsen PC: Screening for prostate cancer is neither appropriate nor cost-effective. Urol Clin North Am 23:521, 1996
3. Albertsen PC et al: Long-term survival among men with conservatively treated localized prostate cancer. JAMA 274:626, 1995
4. American College of Physicians: Screening for prostate cancer. Ann Intern Med 126:480, 1997
5. Barry MJ et al: Differences in how primary care physicians and urologists approach early detection of prostate cancer. J Gen Intern Med 11(Suppl):62, 1996
6. Barry MJ et al: Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part III: Management strategies and outcomes. Urology 46:277, 1995
7. Barry MJ et al: Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program. Urology 46:445, 1995
8. Catalona WJ, Smith DS, Ornstein DK: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: Enhancement of specificity with free PSA measurements. JAMA 277:1452, 1997
9. Coley CM et al: Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. Ann Intern Med 126:394, 1997
10. Coley CM et al: Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. Ann Intern Med 126:468, 1997
11. Coley CM et al: Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part II: Early detection strategies. Urology 46:125, 1995
12. Cooney KA et al: Prostate cancer susceptibility locus on chromosome 1q: A confirmatory study. J Natl Cancer Inst 89:955, 1997
13. Crawford ED et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419, 1989
14. Fleming C et al: A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 269:2650, 1993
15. Gerber GS et al: Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 276:615, 1996
16. Johansson JE et al: Fifteen-year survival in prostate cancer: A prospective, population-based study in Sweden. JAMA 277:467, 1997
17. Lu-Yao GL et al: Follow-up prostate cancer treatments after radical prostatectomy: A population based study. J Natl Cancer Inst 88:166, 1996
18. Morgan TO et al: Age-specific reference ranges for prostate-specific antigen in black men. N Eng J Med 335:304, 1996
19. Oesterling JE et al: Serum prostate-specific antigen in a community-based population of healthy Japanese men: Lower values than for similarly aged white men. Br J Urol 75:347, 1995
20. Oesterling JE et al: Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges. JAMA 270:860, 1993
21. Reissigl A et al: Frequency and clinical significance of transition zone cancer in prostate cancer screening. Prostate 30:130, 1997
22. Robinson JW, Dufour, MS, Fung TS: Erectile functioning of men treated for prostate carcinoma. Cancer 79:538, 1997
23. Smith JR et al: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274:1371, 1996